When Medications Fall Short: Addressing Treatment Gaps in Chronic Migraine

Chronic migraine is not a short-term condition. For most patients, it is a decades-long reality shaped by repeated attacks, layered treatments, and cumulative trade-offs. Clinicians know this. They feel it in every follow-up visit where the question is no longer “Does this work?” but “How long can we keep doing this?”

For patients with high-frequency attacks, the tension is familiar: acute medications remain foundational, yet over time, diminishing returns, tolerability concerns, and the risk of medication overuse headaches (MOH) complicate long-term management. The result is not therapeutic failure, but therapeutic strain.

This is where treatment gaps quietly emerge.

The (not so) quiet pressure of medication overuse

MOH is not a fringe concern in modern migraine. It’s a predictable risk when acute therapies are used frequently, often out of necessity. Even when patients follow instructions carefully, repeated exposure to pharmacologic agents can increase headache frequency, contribute to chronification, and erode quality of life.  

For clinicians, this creates a balancing act: providing timely acute relief while trying to limit cumulative burden. For patients, it can feel like trading one problem for another.

Importantly, none of this negates the value of pharmacologic care. Triptans and OTC medications remain effective for many patients and are supported by evidence. But effectiveness in a single attack is only part of the story in the trajectory of chronic migraine care.

Long-term care requires options that can be used repeatedly, predictably, and safely.  

Why equivalence still matters clinically

In chronic migraine, superiority is not always the most clinically meaningful benchmark. And in many cases, it is not the benchmark clinical studies are designed to achieve. Most Phase III trials in migraine are structured as non-inferiority studies, reflecting the reality that demonstrating comparable effectiveness to established therapies is often both clinically meaningful and methodologically appropriate.

When patients are treating frequent attacks, comparability can carry real weight. An acute option that delivers similar effectiveness without adding systemic exposure may expand flexibility in care, even without demonstrating superiority on traditional endpoints.

This is an important distinction.

A post-hoc analysis comparing remote electrical neuromodulation (REN) to standard care medications offers a useful lens here [1]. Rather than comparing different patient populations, the study used a within-subject design: each participant treated their attacks with their usual medications for four weeks, then treated subsequent attacks with REN only for another four weeks.

This design reflects real clinical decision-making. The comparison is personal, not abstract. Each patient serves as their own control.

What the data reveals, without forcing comparisons

Rather than positioning one acute option against another, this post-hoc analysis is best understood as an examination of how different treatment approaches perform within the same patients over time. Participants first treated attacks using their usual standard-care medications, then later treated subsequent attacks using REN, allowing researchers to observe patterns of response across modalities without introducing a head-to-head superiority claim.  

Within this real-world structure, outcomes such as pain relief, pain freedom, and consistency over repeated use fell within a similar range during both treatment periods [1]. No statistically significant differences were observed, suggesting that REN can achieve meaningful outcomes without introducing additional pharmacologic exposure.

From a clinical perspective, this signal is less about replacement and more about reassurance. The data indicate that incorporating a non-pharmacologic option does not inherently mean sacrificing effectiveness, even for patients with high-frequency attacks.  

Reducing cumulative burden without reducing care

For patients living with chronic migraine, the burden of treatment accumulates. It accumulates biologically, through repeated systemic exposure. It accumulates psychologically, through anxiety about overuse. And it accumulates practically, as patients try to manage work, family, and life between attacks.

Non-pharmacologic options like REN offer a way to offload some of that burden without compromising efficacy [1]. For some patients, this may represents an opportunity to treat attacks without adding to overall medication exposure, while still achieving clinically meaningful relief.  

This distinction is crucial in chronic migraine, where treatment decisions are made repeatedly over time. Having an option that can stand on its own for certain attacks expands how care can be structured, rather than limiting patients to a single default approach.  

Safety also plays a role. In the underlying clinical trial, REN was associated with a low rate of device-related adverse events and no serious device-related events were reported [1]. Over months and years of repeated use, that profile is clinically beneficial.

From replacement to expansion

Discussions around non-pharmacological therapies can sometimes default to comparison. But in chronic migraine care, the more relevant question isn’t what option is better in isolation, but how care can evolve to meet the realities of long-term disease management.

Findings from this analysis support the idea that REN can function as a viable acute treatment option within the broader therapeutic landscape, offering clinicians and patients a non-pharmacologic approach that does not require compromising on effectiveness [1].

For some patients, that may mean choosing a drug-free option more often. For others, it may mean having an alternative available when medications are not preferred or appropriate. Either way, the value lies in expanding what is possible in day-to-day management.

The clinical takeaway

Chronic migraine demands more than short-term efficacy. It demands sustainability.

Data comparing REN to standard-care medications suggest that clinicians can offer a non-pharmacologic option with clinically comparable effectiveness, without forcing an either/or choice [1]. For patients navigating frequent attacks and long treatment horizons, that flexibility can meaningfully alter the trajectory of care.

Sometimes, progress isn’t about doing more. It’s about giving patients another way forward.

Expanding evidence beyond a single study

While the within-patient analysis offers one lens on acute treatment, a broader body of evidence helps contextualize how REN may fit into chronic migraine care over time.

In an open-label study focused on patients with chronic migraine, REN demonstrated consistent response across multiple attacks, with nearly three-quarters of participants achieving pain relief at 2 hours and over 80% demonstrating sustained pain relief at 24 hours in evaluable treatments [2]. Importantly, this study emphasized intra-individual consistency (how reliably a treatment works for the same patient across repeated use) which is highly relevant in high-frequency conditions such as chronic migraine [2].  

Beyond acute treatment, emerging data also reinforces REN’s role in prevention. In a randomized, double-blind, placebo-controlled trial evaluating REN applied every other day, participants experienced a statistically significant and clinically meaningful reduction in monthly migraine days compared to placebo [3]. The observed therapeutic gain of 4 fewer migraine days per month highlights the potential for neuromodulation to contribute to longer-term disease management [3].

These findings are particularly relevant in the context of persistent gaps in preventive care. Despite advances in pharmacologic prevention, adherence remains a challenge, with a substantial proportion of patients discontinuing treatment due to tolerability, efficacy limitations, and other barriers [3]. As a result, many patients who could benefit from preventive strategies remain untreated or undertreated.  

Taken together, this growing evidence reinforces a broader clinical theme: non-pharmacologic options like REN are not confined to a single role. They can contribute across the care continuum, from acute attack management to longer-term reduction in disease burden, while offering a different risk and tolerability profile than systemic therapies.  

The clinical takeaway

Chronic migraine demands more than short-term efficacy. It requires sustainability.

Across multiple studies and use cases, REN demonstrates the ability to deliver clinically meaningful outcomes in both preventive and acute contexts over the span of three years, while maintaining a favorable tolerability profile [1-4]. For clinicians, this supports a more flexible approach to care. One that allows treatment strategies to evolve over time, rather than relying on a single modality.  

Sometimes, progress isn’t about replacing what works but expanding what’s possible.